Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-10
2008-11-18
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266230, C544S284000, C544S293000
Reexamination Certificate
active
07452895
ABSTRACT:
This invention provides quinazoline analogs of Formula I:where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
REFERENCES:
patent: 2583774 (1952-01-01), Hoffman
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 5112817 (1992-05-01), Fukazawa et al.
patent: 5204348 (1993-04-01), Fukazawa et al.
patent: 5405843 (1995-04-01), Fukazawa et al.
patent: 5502187 (1996-03-01), Ayer et al.
patent: 5821246 (1998-10-01), Brown et al.
patent: 6017922 (2000-01-01), Stogniew et al.
patent: 6127374 (2000-10-01), Bridges
patent: 6169091 (2001-01-01), Cockerill et al.
patent: 6184225 (2001-02-01), Thomas et al.
patent: 6225318 (2001-05-01), Sobolov-Jaynes et al.
patent: 6344459 (2002-02-01), Bridges et al.
patent: 6391874 (2002-05-01), Cockerill et al.
patent: 6399602 (2002-06-01), Barker et al.
patent: 6602863 (2003-08-01), Bridges et al.
patent: 6800605 (2004-10-01), Friends et al.
patent: 6828320 (2004-12-01), Cockerill et al.
patent: 6897214 (2005-05-01), Barker et al.
patent: 7081461 (2006-07-01), Mortlock et al.
patent: 7109164 (2006-09-01), Friends et al.
patent: 2002/0169165 (2002-11-01), Kath et al.
patent: 2004/0158065 (2004-08-01), Barth et al.
patent: 2004/0242604 (2004-12-01), Bhattacharya et al.
patent: 2005/0043334 (2005-02-01), Wallace et al.
patent: 2005/0043336 (2005-02-01), Hennequin et al.
patent: 2005/0101616 (2005-05-01), Wallace et al.
patent: 2005/0101617 (2005-05-01), Wallace et al.
patent: 2005/0101618 (2005-05-01), Connell et al.
patent: 2005/0119288 (2005-06-01), Bhattacharya et al.
patent: 2006/0025430 (2006-02-01), Mishani et al.
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/15118 (1996-05-01), None
patent: WO 96/16960 (1996-06-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO 97/30034 (1997-08-01), None
patent: WO 98/02434 (1998-01-01), None
patent: WO 99/09016 (1999-02-01), None
patent: WO 99/24440 (1999-05-01), None
patent: WO 00/31048 (2000-06-01), None
patent: WO 00/42022 (2000-07-01), None
patent: WO 01/94353 (2001-12-01), None
David W. Rusnak, et al., The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo,Molecular Cancer Therapeutics, 2001, vol. 1 (December) pp. 85-94.
David W. Rusnak, et al., The Characterization of Novel, Dual ErbB-2/EGFR, Tyrosine Kinase Inhibitors: Potential Therapy for Cancer,Cancer Research, vol. 61, pp. 7196-7203, Oct. 1, 2001.
Shi, W. et al., “QSAR analysis of tyrosin kinase inhibitor using modified ant colony optimization and multiple linear regression”, European Journal of Medicinal Chemsitry, 2007, pp. 81-86, vol. 42, Elsevier Masson.
First Office Action from the Chinese State Intellectual Property Office (SIPO) dated Mar. 14, 2008.
Buckmelter Alexandre
Lyssikatos Joseph
Topalov George
Wallace Eli
Zhao Qian
Array BioPharma Inc.
Moore John R.
Truong Tamthom N
Wilson James O.
LandOfFree
Quinazoline analogs as receptor tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline analogs as receptor tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline analogs as receptor tyrosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4042452